Search Results

1 - 10 of 171 items :

  • "multiple sclerosis" x
Clear All
Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis

REFERENCES 1. Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics . 2013;10:55-67. 2. Krueger JG, Kircik L, Hougeir F, et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther . 2016;33:1231-1245. 3. Cortese I, Ohayon J, Fenton K, et al. Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology . 2016;86:847-855. 4

Open access
25 Hydroxyvitamin D and Cytokines in Multiple Sclerosis

References 1. Wu GF, Alvarez E. The immunopathophysiology of multiple sclerosis. Neurol Clin 2011;29:257-78. 2. Hollifield RD, Harbige LS, Pham-Dinh D, et al. Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity 2003;36(3):133-41. 3. Brandão CO, Ruocco HH, Farias AS, et al. Cytokines and intrathecal IgG synthesis in multiple sclerosis patients during clinical remission

Open access
Neurophysiological Assessment of Cognitive Dysfunction in Patients with Multiple Sclerosis

ABBREVIATIONS MS – Multiple Sclerosis ERP – Event related potential REFERENCES 1. Hoffmann S, Tittgemeyer M, von Cramon DY.(2007) Cognitive impairment in multiple sclerosis. Curr Opin Neurol 2007; 20(3): 275-80. 2. Amato MP, Zipoli V, Portaccio E.(2006) Multiple sclerosis-related cognitive changes: a review of crosssectional and longitudinal studies. J Neurol Sci 2006; 245(1-2): 41-6. 3. Barker-Collo SL.(2005) Within session practice effects on the PASAT and clients with multiple sclerosis. Arch Neuropsychol Clin. 2005; 20

Open access
Vitamin D Immunomodulatory Potential in Multiple Sclerosis

References 1. Topalov NL. Clinical and epidemiological study of Multiple Sclerosis in Bulgaria [dissertation]. Sofia: Medical university-Sofia;1999. (in Bulgarian) 2. Giesser BS. Primer on Multiple Slcerosis. In: Piccio L, Cross AH. Immunology of Multiple Sclerosis. New York: Oxford University Press;2011:47-56. 3. Smolders J, Damoiseaux J, Menheere P, et al. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008;194:7-17 4. Szodoray P, Nakken B, Gaal J,et al

Open access
Apitherapy Have a Role in Treatment of Multiple Sclerosis

References 1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-17. 2. Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess. 2000;4(27):1-61. 3. Compston A, Coles A. Multiple sclerosis. Lancet. 2002 Apr 6;359(9313):1221-31. Review. Erratum in: Lancet 2002;360(9333):648. 4. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol. 1994;36 Suppl:S6-11. 5

Open access
Multiple Sclerosis Of The Spinal Cord: Is Gadolinium Irreplaceable In Assessing Lesion Activity?

References 1. Bot JC, Barkhof F, Lycklama a Nijeholt G, et al. Differentiation of multiple sclerosis from other infl ammatory disorders and cerebrovascular disease: Value of spinal MR imaging. Radiology. 2002;223:46-56. 2. Sahraian MA, Radue EW-MRI. Gadolinium enhancing lesions in multiple sclerosis, in Atlas of MS lesions. Springer-Verlag, Berlin, 2008, 45-65. 3. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at

Open access
Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze

, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomized, double-blind, placebo-controlled clinical trial. Pain. 2007; (133): 210-220. 22. Rog DJ, Nurmikko TJ, Friede T, Young CA.Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology.2005; (65): 812-819. 23. Seeling W,Kneer L, Buchele B, et al. Delta-9-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative paip

Open access
Higher Serum Uric Acid Levels in Multiple Sclerosis Patients After Longterm Interferon Beta Treatment

References 1. Rodriguez M. (1997) Multiple sclerosis:Insights into molecular pathogenesis and therapy. Mayo Clinic Proc 1997; 72:663-4. 2. Kemp K, Redondo J, Hares K, &Rice C, Scolding N, Wilkins A. (2016) Oxidative injury in multiple sclerosis cerebellar grey matter. Brain Res. 2016 Apr 14. pii: S0006-8993(16)30236-0. doi: 10.1016/j. brainres.2016.04.027. [Epub ahead of print] 3. Beckman JS, Koppenol WH. (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol; 271:C

Open access
Structural and Functional MRI Techniques in Multiple Sclerosis Related Cognitive Dysfunction

REFERENCES 1. Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol 2008;7(9):841-51. 2. Messina S, Patti F. Gray matters in multiple sclerosis: cognitive impairment and structural MRI. Mult Scler Int 2014;2014:609-94. 3. Chiaravalloti N, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008;7(12): 1139-51. 4. Wattjes MP, Geurts JG, Barkhof F. Imaging of gray matter lesions in multiple sclerosis. In: Cohen JA, Rudick RA, eds. Multiple sclerosis therapeutics. 4th Ed. Cambridge University Press

Open access
Correlations between depression, cognitive status, functional scores, disability and lesion load in multiple sclerosis treated with interferon beta 1a

References 1. Luzzio C. Multiple Sclerosis.eMedicine.Medscape. Retrieved 11/25/2014 from http://emedicine.medscape.com/article/1146199-overview 2. Reese JP, Wienemann G, John A, Linnemann A, Balzer-Geldsetzer M, Mueller UO, Eienbroker C, Tackenberg B, Dodel R. Preference-based Health status in a German outpatient cohort with multiple sclerosis. Health Qual Life Outcomes; 2013; 11:162. 3. Sahraian MA, Etesam F. Cognitive Impairment in Multiple Sclerosis. ZJRMS 2014;16(1):1-7 4. Skokou M, Soubasi E

Open access